Free tool
FAERS Monitor: Voraxaze
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125327 or its brand name (Voraxaze, Glucarpidase). Reports on generic versions are filed under their own applications.
Reports
363
Serious
260
72% of reports
Hospitalization
85
Death reported
71
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use92
- underdose62
- laboratory test interference58
- acute kidney injury36
- blood creatinine increased34
- toxicity to various agents34
- drug effect incomplete33
- rebound effect33
- drug ineffective31
- death27
- renal failure25
- mucosal inflammation23
- drug level increased16
- alanine aminotransferase increased15
- false positive investigation result15
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 9 |
| 2014 | 8 |
| 2015 | 17 |
| 2016 | 25 |
| 2017 | 16 |
| 2018 | 56 |
| 2019 | 18 |
| 2020 | 42 |
| 2021 | 41 |
| 2022 | 18 |
| 2023 | 33 |
| 2024 | 21 |
| 2025 | 23 |
| 2026 | 32 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,796 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| laboratory test interferenceSignal | 58 | 4620.8 | 3610.1 | 243,873 |
| false positive investigation resultSignal | 15 | 874.4 | 530.7 | 12,046 |
| rebound effectSignal | 33 | 169.7 | 122.5 | 5,354 |
| drug level increasedSignal | 16 | 56.1 | 34.7 | 811 |
| drug effect incompleteSignal | 33 | 52.7 | 38.1 | 1,623 |
| mucosal inflammationSignal | 23 | 50.9 | 34.3 | 1,077 |
| underdoseSignal | 62 | 49.3 | 39.3 | 2,891 |
| blood creatinine increasedSignal | 34 | 30.2 | 21.9 | 933 |
| alanine aminotransferase increasedSignal | 15 | 14.2 | 8.6 | 171 |
| acute kidney injurySignal | 36 | 13.6 | 10.0 | 412 |
| toxicity to various agentsSignal | 34 | 11.7 | 8.5 | 324 |
| renal failureSignal | 25 | 10.9 | 7.5 | 217 |
| off label useSignal | 92 | 6.1 | 5.1 | 403 |
| death | 27 | 1.8 | 1.3 | 9 |
| drug ineffective | 31 | 1.4 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.